245 related articles for article (PubMed ID: 9579237)
41. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
[TBL] [Abstract][Full Text] [Related]
42. Effect of subclinical hypothyroidism and obesity on whole-body and regional bone mineral content.
Bertoli A; Fusco A; Andreoli A; Magnani A; Tulli A; Lauro D; De Lorenzo A
Horm Res; 2002; 57(3-4):79-84. PubMed ID: 12006702
[TBL] [Abstract][Full Text] [Related]
43. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause.
Jódar E; Muñoz-Torres M; Escobar-Jiménez F; Quesada-Charneco M; Lund del Castillo JD
Clin Endocrinol (Oxf); 1997 Sep; 47(3):279-85. PubMed ID: 9373448
[TBL] [Abstract][Full Text] [Related]
44. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
45. Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders - effects on bone mineral density.
Ricken R; Bermpohl F; Schlattmann P; Bschor T; Adli M; Mönter N; Bauer M
J Affect Disord; 2012 Jan; 136(1-2):e89-e94. PubMed ID: 21757236
[TBL] [Abstract][Full Text] [Related]
46. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
[TBL] [Abstract][Full Text] [Related]
47. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy.
Langdahl BL; Loft AG; Eriksen EF; Mosekilde L; Charles P
Eur J Endocrinol; 1996 Jun; 134(6):702-9. PubMed ID: 8766939
[TBL] [Abstract][Full Text] [Related]
48. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
[TBL] [Abstract][Full Text] [Related]
49. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
Heijckmann AC; Huijberts MS; Geusens P; de Vries J; Menheere PP; Wolffenbuttel BH
Eur J Endocrinol; 2005 Jul; 153(1):23-9. PubMed ID: 15994742
[TBL] [Abstract][Full Text] [Related]
50. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study.
Ross DS
Am J Med; 1993 Oct; 95(4):385-8. PubMed ID: 8213870
[TBL] [Abstract][Full Text] [Related]
51. [The effects of levothyroxine replacement therapy on bone and mineral metabolism in patients with hypothyroidism].
Chai R; Ye Z; Zhan Z; Liu W; Yu M; Liu Y
Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):18-21. PubMed ID: 11798620
[TBL] [Abstract][Full Text] [Related]
52. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
Földes J; Tarján G; Szathmari M; Varga F; Krasznai I; Horvath C
Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
[TBL] [Abstract][Full Text] [Related]
53. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
54. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine.
Kung AW; Pun KK
JAMA; 1991 May 22-29; 265(20):2688-91. PubMed ID: 2023349
[TBL] [Abstract][Full Text] [Related]
55. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.
Stall GM; Harris S; Sokoll LJ; Dawson-Hughes B
Ann Intern Med; 1990 Aug; 113(4):265-9. PubMed ID: 2375563
[TBL] [Abstract][Full Text] [Related]
56. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
[TBL] [Abstract][Full Text] [Related]
57. Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism.
Laway BA; Goswami R; Singh N; Gupta N; Seith A
Clin Endocrinol (Oxf); 2006 Apr; 64(4):405-9. PubMed ID: 16584512
[TBL] [Abstract][Full Text] [Related]
58. Subclinical thyroid dysfunction, bone mineral density, and osteoporosis in a middle-aged Korean population.
Lee K; Lim S; Park H; Woo HY; Chang Y; Sung E; Jung HS; Yun KE; Kim CW; Ryu S; Kwon MJ
Osteoporos Int; 2020 Mar; 31(3):547-555. PubMed ID: 31720711
[TBL] [Abstract][Full Text] [Related]
59. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.
Greenspan SL; Greenspan FS; Resnick NM; Block JE; Friedlander AL; Genant HK
Am J Med; 1991 Jul; 91(1):5-14. PubMed ID: 1858829
[TBL] [Abstract][Full Text] [Related]
60. Current and past menstrual status is an important determinant of femoral neck geometry in exercising women.
Mallinson RJ; Williams NI; Gibbs JC; Koehler K; Allaway HCM; Southmayd E; De Souza MJ
Bone; 2016 Jul; 88():101-112. PubMed ID: 27129885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
